



Full length article

Rhinovirus viremia in adult patients with high viral load in bronchoalveolar lavages



Anneloes L. Van Rijn^{a,*}, Eric C. Claas^a, Peter A. von dem Borne^b, Aloys C.M. Kroes^a,
Jutte J.C. de Vries^a

^a Department of Medical Microbiology, Leiden University Medical Center, Postbox 9600, 2300 RC Leiden, The Netherlands

^b Department of Medical Haematology, Leiden University Medical Center, Postbox 9600, 2300 RC Leiden, The Netherlands

ARTICLE INFO

Keywords:

Rhinovirus

RV

Viremia

Lower respiratory tract infection

BAL

ABSTRACT

Background: In children, rhinovirus viremia has been associated with higher nasopharyngeal loads and increase in severity of clinical signs and symptoms.

Objectives: This study aims to detect rhinovirus viremia in adult patients and to establish potential correlations with the clinical course.

Study design: Adult patients with rhinovirus strongly positive bronchoalveolar lavages (BAL, quantitation cycle, Cq values < 25) detected between 2008 and 2014 were studied retrospectively. Blood sampled between two weeks before and two weeks after BAL sampling was tested for rhinovirus RNA. Underlying conditions, symptoms, radiography, microbiological data, and disease outcome were analysed.

Results: Twenty-seven of 43 patients with rhinovirus positive BAL at Cq values < 25 had blood samples available within the prespecified time-frame (mean blood 3–4 samples per patient). Four of these 27 patients (15%) tested rhinovirus RNA positive in their blood (of whom one patient twice). Genotyping demonstrated rhinovirus A01, A24, B52 and B92 in these four immunocompromised patients.

Viremic patients were not significantly different with regard to underlying conditions, respiratory symptoms, radiological findings, co-pathogens nor the number of blood samples tested for RV. However, patients with rhinovirus viremia had significant higher mortality rates compared to patients without viremia, as all four died as a consequence of respiratory problems (100%) versus 22% (5/23), $p = 0.007$ (Fisher's exact).

Conclusions: Rhinovirus viremia can occur in adult patients with a high viral load in BAL fluid. Rhinovirus viremia may be considered a negative prognostic factor, although a causative role with regard to the adverse outcome has yet to be demonstrated.

1. Background

Rhinovirus (RV) is the most common virus found in respiratory tract infections in children and adults [1–3]. Rhinovirus primarily results in mild upper respiratory tract infections, known as the “common cold”. However, a role for rhinovirus in lower respiratory tract infections has also been described. Rhinovirus was detected in 2–17% of the community acquired pneumonias [4–8], in children even up to 26% [9]. Severe rhinovirus-associated pneumonias may givesimilar symptoms and rates of mortality as severe influenza-associated pneumonia, but are more likely to occur in immunocompromised [10]. Generally, the clinical picture of rhinovirus infections appears to be more severe in patients with a higher viral load and in elderly patients, immunocompromised hosts and patients with underlying chronic lung

diseases [11–15]. Although rhinovirus C has been implicated in more severe disease [16], other studies failed to show differences in clinical picture between different rhinovirus species [17–19].

In several case reports and prospective case series, rhinovirus RNA has been demonstrated in blood of paediatric patients [20–27]. Approximately 12% of the children with rhinovirus respiratory infections were found to be viremic on admission. This percentage dropped to 7% on day three after admission [23,25]. Of the viremic paediatric patients, the majority were infected with rhinovirus C, varying from 67 to 87% [20,23]. Viremia was associated with a history of asthma, higher nasopharyngeal viral loads and more severe clinical signs and symptoms [20,25]. In addition, case reports on rhinovirus viremia have been published in patients with fatal outcome, suggesting a correlation with more severe disease [21,26,27]. Rhinovirus viremia in adult patients

* Corresponding author.

E-mail addresses: a.l.van_rijn-klink@lumc.nl (A.L. Van Rijn), e.c.j.claas@lumc.nl (E.C. Claas), p.a.von_dem_Borne@lumc.nl (P.A. von dem Borne), a.c.m.kroes@lumc.nl (A.C.M. Kroes), j.j.c.de_vries@lumc.nl (J.J.C. de Vries).

<http://dx.doi.org/10.1016/j.jcv.2017.10.007>

Received 9 June 2017; Received in revised form 29 September 2017; Accepted 11 October 2017

1386-6532/ © 2017 Elsevier B.V. All rights reserved.

has not yet been demonstrated. Rhinovirus RNA was analysed in adult patients, inoculated with rhinovirus-16, by deMore et al. [28] This group found no evidence of viremia. However this were healthy subjects, or with mild asthma, with upper respiratory tract symptoms not requiring hospitalisation.

2. Objectives

The aim of this study was to determine whether rhinovirus viremia occurs in adults and whether there is a relationship with the clinical course of the infection.

3. Study design

3.1. Patients and samples

A laboratory database (GLIMS, MIPS, Belgium) search was performed for bronchoalveolar lavages (BAL) in adults between January 2008 and June of 2014 in the tertiary care hospital Leiden University Medical Center (LUMC, Leiden, the Netherlands). All BAL samples were included in the initial selection, however this invasive diagnostic procedure is performed primarily in respiratory insufficient and immunocompromised patients. Adult patients with a rhinovirus PCR positive BAL and a quantitation cycle (Cq) value of 25 and below were considered strongly positive, described as risk factor for RV viremia in children [20], and included in the study. Of these patients, stored plasma (-80 °C) or serum (-20 °C) samples (previously sent to the microbiological lab for routine diagnostics) were collected (serum when plasma was not available). All samples available in the time period from two weeks before to two weeks after BAL sampling, with a maximum of one per day, were tested for the presence of rhinovirus RNA.

Patient characteristics, underlying diseases, symptoms, laboratory values, chest radiography, and disease outcome were retrospectively obtained from the patient records and laboratory databases. Stem cell transplantation patients were routinely screened for reactivation of cytomegalovirus (CMV), Epstein Barr virus and adenovirus by viral load testing.

3.2. Rhinovirus RNA detection

Nucleic acids were extracted from thawed serum or plasma samples with the MagNA Pure LC, using the Total Nucleic Acid Isolation Kit – Large Volume (Roche Diagnostics). The input was 1000 µl serum or plasma with elution of 50 µl extracted nucleic acid. If insufficient clinical sample was available, negative plasma was added up to 1000 µl.

Rhinovirus RNA amplification was performed in duplicate with an in-house real-time polymerase chain reaction (amplifying a 142-bp fragment of the 5'-UTR region), all samples in one run simultaneously, using primers, probes and conditions previously described by Loens et al. [29]. Cq values, normalized using a fixed fluorescence threshold, were used as an indicative measure of viral load. Rhinovirus typing of respiratory samples from viremic patients was performed by amplification and sequencing of the VP4/VP2 genome region as previously described by Zlateva et al. [30].

3.3. Statistical analysis

Underlying respiratory illnesses, transplantation status, symptoms, radiographic changes, microbiologic findings, and outcome of rhinovirus viremia positive patients were compared to rhinovirus viremia negative patients. Categorical data were compared using 2×2 tables with Fisher's exact test and Odds ratios. Numeric variables were compared using the independent *t*-test for equality of means.

All statistical analysis was performed using IBM SPSS Statistics version 20.00 software for Windows.

3.4. Ethical approval

The study design was approved by the medical ethics review committee of the LUMC.

4. Results

4.1. Patient selection

Between January 2008 and June of 2014, 791 bronchoalveolar lavages from 638 adult patients were tested for rhinovirus RNA. A total of 114 BAL samples from 84 (13%) patients tested positive for rhinovirus (range Cq values 15–45, randomly distributed, data not shown). Of 43 patients (51%, 48 BAL samples), the RV PCR result had a Cq < 25. A total of 84 blood samples were available from 27 of these 43 patients (63%), on average three- four blood samples per BAL sample (31 BAL samples). In 14 samples from nine patients, the available plasma volume varied from 200 to 950 µl.

4.2. Rhinovirus viremia positive patients

Four out of the 27 patients (15%) with BAL RV Cq < 25 tested rhinovirus RNA positive in their blood samples (range Cq values 34–42) divided over the years 2010, 2011 and 2012. From these viremic patients a total of 22 blood samples were tested of which five tested positive. One patient was found viremic twice, on day –six and day +three relative to BAL sampling. For an overview of tested blood samples relative to the day of the BAL see Fig. 1.

4.3. Genotyping of RV viremic patients

The rhinovirus load in the blood samples of the viremic patients was considered too low to enable successful genotyping. Therefore, the associated BAL samples were used, which resulted in two patients with RV-A: A24 and A01, and two patients with RV- B: B52 and B92.

4.4. Characteristics of rhinovirus viremic patients

Patient 1 (Fig. 1), was a 60-year-old female who received allogeneic stem cell transplantation for multiple myeloma. One month after transplantation she was admitted at the haematology department with neutropenic fever with a leukocyte count of 0.1×10^9 g/L. During her stay in the hospital she developed cough and dyspnoea. One day after symptom onset a BAL was performed, which was positive for rhinovirus A01 (Cq 24), parainfluenza 2 (Cq 15), adenovirus (Cq 35) and tested galactomannan positive. Bacterial culture showed *Stenotrophomonas maltophilia*. One of six blood samples tested RV positive, Cq 42. Fourteen days after the BAL was performed the patient died with multiple, respiratory and systemic infections (CMV reactivation- Aspergillus pneumonia- *Stenotrophomonas bacteraemia*) and unexplained on-going neutropenia. No autopsy was performed. The last two blood samples before her death were RV negative.

Patient 2, was a 68-year-old male with myelodysplastic syndrome for which he received non-myeloablative allogeneic stem cell transplantation four months prior to admittance to the intensive care unit (ICU) due to respiratory failure. At that time leukocyte count was 3.6×10^9 /L and lymphocyte count 0.6×10^9 /L. Four days after symptom onset a BAL was performed, in which a rhinovirus RV-B52 (Cq 23), was detected. No other pathogen (viral, bacterial, parasitic or fungal) could be found in the BAL sample. In total three blood samples were tested. The blood samples drawn six days before and three days after the BAL tested rhinovirus positive, Cq 34–36. The blood sample drawn three days before the BAL was rhinovirus negative. The patient died 11 days after the BAL was performed. Autopsy showed extensive pulmonary fibrosis, the lung architecture was completely destroyed without specific characteristics. Reported cause of death was

Download English Version:

<https://daneshyari.com/en/article/5667980>

Download Persian Version:

<https://daneshyari.com/article/5667980>

[Daneshyari.com](https://daneshyari.com)